Table 2.
Correlation between CDX2 expression and the clinicopathological parameters
| Variables | Categories | CDX2 score | P-value | |
|---|---|---|---|---|
| Negative | Positive | |||
| Total | 46(100%) | 34(100%) | ||
| Gender | Male | 25(54.3%) | 19(55.9%) | 0.892 |
| Female | 21(45.7%) | 15(44.1%) | ||
| Age groups | ≤50 years | 14(28.6%) | 2(6.5%) | 0.02 |
| >50 years | 35(71.4%) | 29(93.5%) | ||
| Tumor type | Intestinal type | 27(58.7%) | 21(61.8%) | 0.782 |
| Diffuse type | 19(41.3%) | 13(38.2%) | ||
| Tumor grade | Well-moderately differentiated | 21(45.7%) | 12(35.3%) | 0.352 |
| Poorly differentiated | 25(54.3%) | 22(64.7%) | ||
| lymphovascular invasion | Positive | 38(82.6%) | 26(76.5%) | 0.497 |
| Negative | 8(17.4%) | 8(23.5%) | ||
| Nodal status | Positive | 39(84.8%) | 30(88.2%) | 0.751 |
| Negative | 7(15.2%) | 4(11.8%) | ||
| Tumor stage | 1-2 | 13(28.3%) | 11(32.4%) | 0.309 |
| 3-4 | 33(71.7%) | 23(67.6%) | ||